DNA sequencing

Dr. Gary Nakhuda to Present Insights on Mosaic Embryo Transfer at CFAS Annual Meeting 2023

Retrieved on: 
Thursday, September 21, 2023

VANCOUVER, British Columbia, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce the participation of its co-founder and co-director, Dr. Gary Nakhuda, as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023, an annual meeting of professionals in reproductive medicine and science.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce the participation of its co-founder and co-director, Dr. Gary Nakhuda, as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023, an annual meeting of professionals in reproductive medicine and science.
  • Furthermore, Dr. Nakhuda will discuss insights from Olive's extensive data and experience with PGT-A, adding an invaluable layer of real-world context to the discussion.
  • Dr. Gary Nakhuda explains, "Embryonic mosaicism refers to the co-existence of cells with normal chromosome complements and others with apparent abnormalities.
  • Dr. Gary Nakhuda's presentation promises to be a significant contribution to the CFAS 2023 event, offering valuable insights that could shape the future of reproductive medicine.

CENTOGENE Reports First Half 2023 Financial Results

Retrieved on: 
Thursday, September 7, 2023

and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its unaudited financial results for the six months ended June 30, 2023.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its unaudited financial results for the six months ended June 30, 2023.
  • Cost of sales increased by €2,692 thousand, or 20.7%, to €15,728 thousand for the first half of 2023, from €13,036 thousand for the first half of 2022.
  • General administrative expenses decreased by €112 thousand, or 0.6%, to €17,172 thousand for the first half of 2023, from €17,284 thousand for the first half of 2022.
  • The decrease is mainly due to the increase in consumable expenses on approximately €1,601 thousand for the first half of 2023.

Element Biosciences Announces Over 100 Commercial Orders of its AVITI System and Surpasses Q2 Sales Goals

Retrieved on: 
Wednesday, September 6, 2023

/PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced it has exceeded 100 orders of the AVITI System. With U.S. and international customers in 13 countries, Element has expanded its commercial team globally through direct sales and distribution networks. The company has seen triple digit quarter-on-quarter growth since launch, and in Q2 reached an estimated 15 percent of the total sales of mid-throughput sequencing instruments, just one year after its first commercial shipments. Element has also signed distribution agreements with 11 distributors across the globe.

Key Points: 
  • With U.S. and international customers in 13 countries, Element has expanded its commercial team globally through direct sales and distribution networks.
  • "Today's milestone validates the market demand for truly differentiated solutions that help customers achieve more with sequencing, regardless of scale.
  • "As a data-driven company, we are committed to setting ambitious goals and consistently delivering data and outcomes that surpass expectations.
  • Over 40 percent of sales were multi-unit orders and Element also welcomed repeat customers adding capacity to their existing fleet of AVITI instruments.

Next Generation Sequencing in Agrigenomics Market Research Report 2023: From Seeds to Solutions - Addressing Food Security & Revolutionizing Farming - ResearchAndMarkets.com

Retrieved on: 
Friday, August 18, 2023

The "Next Generation Sequencing in Agrigenomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next Generation Sequencing in Agrigenomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global next-generation sequencing (NGS) in the agrigenomics market is anticipated to observe impressive growth during the forecast period 2023-2027.
  • Agrigenomics is basically an application of genomics in the agriculture region, which is used to enhance the productivity and sustainability of livestock and crop.
  • The surge in demand for food among people across the globe is propelling the growth of the market.

Revolutionizing Liquid Biopsy: Zymo Research and Opentrons Partner to Automate Novel Cell-Free DNA Isolation Chemistry

Retrieved on: 
Monday, July 24, 2023

IRVINE, Calif., July 24, 2023 /PRNewswire/ -- Zymo Research Corp, a leading provider of life science technologies, has partnered with Opentrons Labworks, Inc., a leader in lab automation, to revolutionize cell-free DNA isolation and analysis. The collaboration brings an innovative fully automated, comprehensive workflow from sample collection through library preparation transforming liquid biopsy analysis.

Key Points: 
  • IRVINE, Calif., July 24, 2023 /PRNewswire/ -- Zymo Research Corp , a leading provider of life science technologies, has partnered with Opentrons Labworks, Inc., a leader in lab automation, to revolutionize cell-free DNA isolation and analysis.
  • Current, common methods of liquid biopsy extraction can be challenging for cancer research due to inefficient recovery of cell-free DNA.
  • The Zymo Research and Opentrons partnership offers a new approach that overcomes the hurdles of these common methods.
  • Zymo Research will be at booth #3089 and Opentrons will be at booth #1978.

Global Next Generation Sequencing (NGS) Market Analysis and Forecast, 2023-2033 - Decreasing Genome Sequencing Costs and Government Initiatives Propel NGS Technology to New Heights - ResearchAndMarkets.com

Retrieved on: 
Monday, July 24, 2023

This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing.

Key Points: 
  • This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing.
  • The opportunity for growth of the global NGS market lies in the development of economical and portable technologies.
  • The global NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.
  • The global NGS market (by sequencing) is expected to be dominated by the targeted sequencing segment.

Genedata Announces Licensing Agreement with Gilead Sciences to Enhance Data Science Innovation in Discovery Research

Retrieved on: 
Thursday, July 20, 2023

BASEL, Switzerland, July 20, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced a licensing agreement with Gilead Sciences, Inc. to help the company leverage the power of multi-omics data in the discovery of life-changing therapeutics across multiple indications. The agreement includes a software license to Genedata Profiler®, a domain-specific, state-of-art data integration and analytics platform, and access to consulting resources to support the adoption and integration of the solution within the company's infrastructure.

Key Points: 
  • The agreement includes a software license to Genedata Profiler ®, a domain-specific, state-of-art data integration and analytics platform, and access to consulting resources to support the adoption and integration of the solution within the company's infrastructure.
  • "At Gilead, we work every day to discover innovative therapeutics for people with life-threatening diseases," said Li Li, Executive Director, Research Data Sciences at Gilead.
  • "Utilizing Genedata Profiler will enhance our capabilities for integration and analysis of large-scale multi-modal datasets as we continue to accelerate research for the discovery of transformative medicines."
  • "We are excited to have signed Gilead Sciences to our rapidly growing customer list for our Genedata Profiler platform," said Othmar Pfannes, Ph.D., CEO of Genedata.

Ultima Genomics Adds Tenured Strategic and Technology Leadership In Preparation for Commercial Launch

Retrieved on: 
Monday, June 26, 2023

Shlomey Derhi will join the Company's R&D and engineering leadership as Head of Architecture and Integration and will be focused on accelerating technology development of the Company's unique sequencing architecture.

Key Points: 
  • Shlomey Derhi will join the Company's R&D and engineering leadership as Head of Architecture and Integration and will be focused on accelerating technology development of the Company's unique sequencing architecture.
  • "We are excited to have two proven and tenured industry leaders join our leadership team at this important stage of our Company," said Gilad Almogy, CEO and founder of Ultima Genomics.
  • She has deep scientific, technical and commercial expertise and will be instrumental in driving customer success, strategy and commercial focus as we transition from early access to commercial launch.
  • He will be pivotal as we prepare our first product, the UG100™ for commercial launch, and continue to advance our unique sequencing architecture."

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide

Retrieved on: 
Friday, June 2, 2023

Massive Bio , a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC) , a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools.

Key Points: 
  • Massive Bio , a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC) , a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools.
  • The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS).
  • View the full release here: https://www.businesswire.com/news/home/20230602005015/en/
    Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide (Graphic: Business Wire)
    Selin Kurnaz PhD , Founder and CEO of Massive Bio, commented, "We are thrilled to be working with the Precision Cancer Consortium to advance precision oncology through our innovative AI analytics tools.
  • With this partnership, we can streamline the process of clinical trial matching and reduce the burden on patients and healthcare systems."

CENTOGENE Reports Full Year 2022 Financial Results

Retrieved on: 
Tuesday, May 16, 2023

and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.
  • “2022 reaffirms CENTOGENE’s focus and dedication to becoming the essential data-driven partner in rare and neurodegenerative diseases.
  • By strategically managing our expenses, we seek to enhance the stability of our balance sheet and foster sustainable financial performance,” added Miguel Coego, Chief Financial Officer at CENTOGENE.
  • These customizable partnering solutions include Insight Reports, which are tailored data analysis reports that seamlessly enable partners to answer ad hoc research questions via real-world data.